NEW YORK, Sept. 22, 2026 (GLOBE NEWSWIRE) — Wolf Popper LLP is investigating potential claims on behalf of purchasers of Xenon Pharmaceuticals Inc. (“Xenon”) common stock (NASDAQ: XENE).
Xenon is a clinical-stage drug company, and its lead drug candidate is Azetukalner (formerly XEN1101), a selective Kv7 potassium-channel opener designed to reduce excessive neuronal activity in the brain. Xenon is developing Azetukalner for neurological and psychiatric disorders, principally focal-onset seizures, major depressive disorder (MDD), and bipolar depression. In January 2025, Xenon announced it initiated its Phase 3 X-NOVA2 trial which would recruit 450 patients and give them the 20-mg dose of Azetukalner to treat MDD.
After the market closed on September 17, 2026, Xenon announced it “implemented a voluntary pause on enrollment for the new patients in its ongoing clinical studies in major depressive disorder (MDD) and bipolar depression, following an analysis of neuropsychiatric adverse events in these studies. On that news, Xenon’s stock price fell $17.60 per share to $39.75 on September 15, 2026, down 30.7% on very heavy volume.
Investors who suffered losses trading in Xenon common stock and who would like to discuss the investigation should contact Adam Savett at (212) 451-9655, or [email protected].
Wolf Popper has successfully recovered billions of dollars for defrauded investors. Wolf Popper’s reputation and expertise have been repeatedly recognized by courts that have appointed the firm to major positions in securities litigation. For more information about Wolf Popper, please visit the Firm’s website at www.wolfpopper.com.
May Be Considered Attorney Advertising in Certain Jurisdictions.
Prior Results Do Not Guarantee a Similar Outcome.
Wolf Popper LLP
Adam Savett. Esq.
570 Lexington Avenue
New York, NY 10022
Tel.: (212) 451-9655
Email: [email protected]
